CARKey: a CAR-T Platform to Mitigate Tumour Antigen Heterogeneity & On-Target-off Tumour Toxicity

• Development of CARKey platform technology with multireceptor targeting
• Identification of combinatorial target proteins through bioinformatic analysis
• Rapid and strategic development of clinical candidate

New Data

Speakers:

John Bridgeman

Chief Scientific Officer

Immunokey